CoChat

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival.Methods This double-blind, placebo-controlled trial was undertaken in 974 hospitals in 42 countries. 18,695 patients with previously manifest or increased risk of vascular disease were randomly assigned to receive either rimonabant 20 mg (n=9381) or matching placebo (n=9314). Randomisation was stratified by centre, implemented with an independent interactive voice response system, and all study personnel and participants were masked to group assignment. The primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke, as determined via central adjudication. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00263042.Findings At a mean follow-up of 13.8 months (95% CI 13.6-14.0), the trial was prematurely discontinued because of concerns by health regulatory authorities in three countries about suicide in individuals receiving rimonabant. All randomised participants were analysed. At the close of the trial (Nov 6, 2008), the composite primary endpoint of cardiovascular death, myocardial infarction, or stroke occurred in 364 (3.9%) patients assigned to rimonabant and 375 (4.0%) assigned to placebo (hazard ratio 0.97, 95% CI 0.84-1.12, p=0.68). With rimonabant, gastrointestinal (3038 [33%] vs 2084 [22%]), neuropsychiatric (3028 [32%] vs 1989 [21%]), and serious psychiatric side-effects (232 [2.5%] vs 120 [1.3%]) were significantly increased compared with placebo. Four patients in the rimonabant group and one in the placebo group committed suicide.Interpretation The premature termination of this trial has important lessons for drug development. A drug that was being marketed for weight loss, but being tested for improving cardiovascular outcomes, induced a level of serious neuropsychiatric effects that was deemed unacceptable by regulatory authorities, and both the drug and the trial were abruptly terminated.Funding Sanofi-Aventis.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(10)60935-x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 15 references

Cited by

See all 292

Metadata

Authors
Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., Job, B., Murphy, J. H., & Bhatt, D. L.
Affiliations
  • Hôpital Lariboisière (FR)
  • University of Edinburgh (GB)
  • Brigham and Women's Hospital (US)
  • Brown University (US)
  • Kerckhoff Klinik (DE)
  • Pitié-Salpêtrière Hospital (FR)
  • University of Rochester (US)
  • Sunnybrook Health Science Centre (CA)
  • Sanofi (France) (FR)
  • VA Boston Healthcare System (US)
Corresponding author
Topol, Eric J
Venue
The Lancet
Publisher
Elsevier BV
Published
2010-08
Volume
376
Issue
9740
Pages
517-523
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2112222692
Cited by
266
References
15
Citations by year
2026: 8 · 2025: 15 · 2024: 15 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 14 · 2019: 14 · 2018: 10 · 2017: 21 · 2016: 21 · 2015: 16 · 2014: 17 · 2013: 15 · 2012: 26
FWCI
19.48
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Libraries (submittedVersion)
  • ORBi (University of Liège) (submittedVersion)
Funders
  • Sanofi
  • Cleveland Clinic
  • Institute of Clinical and Translational Sciences
  • National Center for Research Resources (UL1RR025774)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
rimonabant, cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, cardiovascular risk, obesity, neuropsychiatric adverse effects, suicide risk, gastrointestinal adverse effects, drug safety, trial termination, anti-obesity drugs, drug development, cardiovascular disease prevention, primary prevention of cardiovascular disease, secondary prevention of cardiovascular disease
MeSH terms
Rimonabant, Aged, Aged, 80 and over, Mental Disorders, Cardiovascular Diseases, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Obesity, Piperidines, Pyrazoles, Suicide, Drug Approval, Cannabinoid Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(10)60935-x
The paper
Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., Job, B., Murphy, J. H., & Bhatt, D. L. (2010). Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(10)60935-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.